Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study

Lewis, K.Robert, C.Ascierto, P. A.Munhoz, R.Liszkay, G.de la Cruz Merino, L.Olah, J.Queirolo, P.Mackiewicz, J.Li, H.Zhu, Q.McKenna, E.McNally, V.Gutzmer, R.McArthur, G.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27615enIncidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 studyconference outputopen access10.1016/j.annonc.2020.08.12601569-8041http://www.annalsofoncology.org/article/S0923753420412566/pdf573469101424